INTERMITTIERENDE DOSIERUNG EINES MDM2-INHIBITORS

Patent europeic · EP3160463 · Stritgà

Inscripziun en il register

Numer da publicaziun
EP3160463
Numer da la dumonda
EP15733926
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
Stritgà
Scrittira da patent
Concedì
Annunzià
25-06-2015
Publitgà
03-05-2017
Concedì
21-10-2020
Stritgà
21-01-2022
Motiv
Taxa annuala betg pajada
Classas IPC
A61K 31/402 (2006.01)
A61K 31/404 (2006.01)
A61K 31/4178 (2006.01)
A61K 31/4418 (2006.01)
A61K 31/4439 (2006.01)
A61K 31/47 (2006.01)
A61K 31/472 (2006.01)
A61K 31/496 (2006.01)
A61P 35/00 (2006.01)
Prioritad
US 201462017406 P 26.06.2014
Dumonda PCT
PCT/IB2015/054792 25.06.2015
Publicaziun PCT
WO2015/198266 30.12.2015
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 15-11-2023

    Midada

    Published in Swissreg on 15.11.2023

  2. 07-03-2023

    Midada

    Published in Swissreg on 07.03.2023

  3. 21-01-2022

    Stritgà, taxa betg pajada

    Published in Swissreg on 21.01.2022

  4. 23-09-2021

    Midada

    Published in Swissreg on 23.09.2021

  5. 21-10-2020

    Concedì

    Published in Swissreg on 21.10.2020

Partidas

Possessur

Novartis AG

Lichtstrasse 35, 4056 Basel

Inventur

JEAY, Sebastien

CH-4002 Basel

FERRETTI, Stephane

CH-4002 Basel

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.